Long-term study of IGE025 in moderate to severe bronchial asthma.

Trial Profile

Long-term study of IGE025 in moderate to severe bronchial asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 24 Oct 2011 Actual initiation date (Nov 2003) added as reported by ClinicalTrials.gov.
    • 24 Oct 2011 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
    • 11 Jun 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top